The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
IMS 2022 | Improving the QoL of patients with multiple myeloma treated with CAR-T therapy
Surbhi Sidana, MD, Mayo Clinic, Stanford, CA, talks on the quality of life (QoL) of patients with multiple myeloma treated with ciltacabtagene autoleucel (cilta-cel) and idecabtagene vicleucel (ide-cel) from the CARTITUDE-1 (NCT03548207) and KarMMa (NCT03361748) studies, highlighting the importance of improving the burden of symptoms patients experience after CAR-T therapy. This interview took place at the 19th International Myeloma Society Meeting (IMS) held in Los Angeles, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
